Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    BusinessNewsAsia.comBusinessNewsAsia.com
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    BusinessNewsAsia.comBusinessNewsAsia.com
    Home»HealthCare»Graphene quantum dots show promise in targeting Parkinson’s-related protein clumping
    HealthCare

    Graphene quantum dots show promise in targeting Parkinson’s-related protein clumping

    Marie JonesBy Marie JonesMay 20, 2026Updated:May 21, 2026No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Engineered carbon-based nanomaterials can interfere with the aggregation of misfolded proteins linked to neurodegenerative diseases, offering a new direction for future therapeutic exploration.

    The buildup of a protein called -synuclein (ASN) into toxic clumps is a hallmark of synucleinopathies, a group of neurodegenerative diseases that includes Parkinson’s and multiple system atrophy (MSA).

    These aggregates are associated with cellular dysfunction and lead to progressive neuronal loss. Because current treatments only manage symptoms rather than stopping the underlying protein clumping, scientists are exploring new strategies, including nanomaterials that can prevent these aggregates from forming or help clear them from the brain.

    A multinational research team led by Professor Małgorzata Kujawska at the Poznań University of Medical Sciences in Poznań, Poland, has found that graphene quantum dots (GQDs)—nanoscale carbon particles—can counteract this clumping process.

    In a study published in the journal Science and Technology of Advanced Materials (STAM), the researchers detailed how these dots interact with ASN to prevent it from forming the long, toxic fibers that characterize the disease.

    “This study points to a promising new direction for strategies against neurodegenerative diseases,” says Professor Kujawska. “While clinical use of GQDs remains a long way off, these findings strengthen the case for further research.”

    The study used a multi-stage approach, testing the GQDs in cell-free environments, neuronal cultures, and animal models of MSA. The researchers found that when GQDs were administered intranasally in mice, the particles significantly reduced the presence of toxic protein aggregates. Furthermore, the treatment appeared to activate autophagy, a biological recycling process that helps cells break down and remove damaged proteins.

    At concentrations relevant to its biological effects, the GQD showed a favorable safety profile, although some changes in cellular stress and immune responses were observed at higher doses. This is an important consideration, as many nanomaterials face hurdles in medical applications due to concerns over long-term biocompatibility.

    While the results are promising, challenges remain, such as preventing quantum dots from clumping in liquid suspensions. “GQDs may serve as a useful research tool,” says Professor Kujawska. “What we learn as we optimize their properties and conduct a comprehensive safety evaluation could help design more effective nanomaterial-based strategies not just for synucleinopathies, but also for other conditions characterized by the buildup of toxic proteins.”

    Further information
    Małgorzata Kujawska
    Poznań University of Medical Sciences
    kujawska@ump.edu.pl

    Paper: https://www.tandfonline.com/doi/full/10.1080/14686996.2026.2662693

    About Science and Technology of Advanced Materials (STAM)

    Open access journal STAM publishes outstanding research articles across all aspects of materials science, including functional and structural materials, theoretical analyses, and properties of materials. https://www.tandfonline.com/STAM

    Dr. Kazuya Saito
    STAM Publishing Director
    SAITO.Kazuya@nims.go.jp

    Image:

    Caption: Nanoscale carbon particles offer a new insight into possible therapies for neurodegenerative diseases, including Parkinson’s and multiple system atrophy.

    Press release distributed by Asia Research News for Science and Technology of Advanced Materials.

    Asia Research News Science and Technology of Advanced Materials
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleXero Launches Lite Plan in Indonesia to Help Indonesian Small Businesses Master Their Finances
    Next Article CTF Life Launches Hong Kong’s First Indexed Universal Life Insurance Plan Linked to BNP Paribas’ Indices

    Related Posts

    ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801’s Renoprotective Potential in Oral Presentation

    June 5, 2026

    Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market

    June 4, 2026

    Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

    June 4, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.